Stamulumab

Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research[1][2].

Research Areas >> Metabolic Disease

Stamulumab (MYO-029;腹腔给药; 1-10 mg/kg/周; 持续 12 周) 在 SCID 小鼠体内以浓度依赖性方式增加骨骼肌质量。Stamulumab 导致肌纤维肥大而不是增生[1]。 Stamulumab (静脉注射; 1, 5, 20, 100 mg/kg/周; 持续 4 周) 在 C57/SCID 小鼠中的中心清除率 (CL) 为 0.25 mL/h/kg[1]. Pharmacokinetic Parameters of Stamulumab (MYO-029)[1]. C57/SCID mice IV (1-100 mg/kg/week for 4 weeks) Sprague Dawley rats (2-50 mg/kg; single injection) Cynomolgus monkeys (10-100 mg/kg/week for 5 or 39 weeks) CL (mL/h/kg) 0.245 0.542 0.228 Volume of central compartment (mL/kg) 103 58.9 41.8 Distributive clearance (mL/h/kg) 1.79 0.815 Animal Model: Female SCID mice[1] Dosage: 1, 2.5, 5, 10 mg/kg Administration: IP; every week for 12 weeks Result: Increased skeletal muscle mass in vivo in a concentration‐dependent manner.

[1]. P Singh, et al. Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy. Clin Transl Sci. 2016 Dec;9(6):302-310.  

[2]. Kathryn R Wagner, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008 May;63(5):561-71.